KIN-2787

· Pierre Fabre Medicament

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KIN-2787, covering 2025-12-24 to 2025-12-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors [Phase 1]